Anders Boysen,

CEO, Co-founder and Co-inventor

Anders Boysen is Chief Executive Officer and Co-inventor of GlyProVac’s proprietary BEMAP technology. Anders Boysen focus on the technical and scientific aspects of GlyProVac ApS operations. Prior to founding GlyProVac ApS, Anders Boysen over the last four years worked to establish proof of concept of the GlyProVac hypothesis and technically mature the lead antigen at University of Southern Denmark. Anders Boysen holds a Ph.D. in molecular biology and has more than 15 years of experience in the fields of molecular microbiology, human bacterial pathogens and biological mass spectrometry, both in academia and in the Danish vaccine development company ACE Biosciences Aps.


Ann Zahle Andersen,

COO and Co-founder

Ann Zahle Andersen is chief operations officer at GlyProVac ApS with responsibility of daily operations at GlyProVac including IP, contracts, fundraising and finances. Prior to founding GlyProVac ApS, Ann Zahle Andersen has been involved in business development of the GlyProVac hypothesis and lead antigen since the inception of the BEMAP method in 2013. Ann is an ASTP certified technology transfer professional with a Ph.D. in Biochemistry, experience in the field of microbiology and food borne bacteria as well as 5 years of experience in all aspects of business development of research-based inventions.


Mette Thorsing,



Mette Thorsing works in GlyProVac and is in charge of the company’s cloning program. From more than 10 years of experience in the fields of molecular microbiology, bacterial physiology and human pathogens, she has accumulated knowledge and skills that are put to use in the laboratory and in the planning of GlyProVac’s scientific operations. Mette holds a Ph.D in molecular microbiology.


Julie Ingerslev Bæk-Andersen,

Laboratory Technician


Julie Ingerslev Bæk-Andersen is an experienced QC laboratory technician and is in charge of the company’s antigen production and cell-based assays. Julie has more than 10 years of experience in quality control and GMP from both industry and hospital setting. She has a strong instinct for order and keeps focus on SOP development, traceability, and in-process as well as release-controls in the GlyProVac daily operations.  


Christiane Juhls

Clinical Vaccine Development Lead


Christiane Juhls is complementing the GlyProVac team with her long standing experience in guiding international interdisciplinary teams in pre-clinical and early clinical development, including 19 years of translational vaccine R&D. She provides strategic and regulatory guidance and support to the GlyProVac management incl. Target Product Profile building and Clinical trial design.


Thøger Jensen Krogh,

Bioinformatics & IT Specialist


Thøger Jensen Krogh holds a Ph.D. in biochemistry & molecular biology with a focus on microbiologi and bioinformatics. Skills within building databases, omics data analysis, and app creation. He uses his cross disciplinary skillset to develop bioinformatics tools and solutions to support BEMAP based GlyProVac glyco-protein analysis. In addition, he maintains the IT infrastructure and homepage of GlyProVac.


Board of directors

Kirsten Winther (appointed by SDI, Chairman), Ann Zahle Andersen (appointed by the founders), Allan Rosetzsky (appointed by investors), Wian de Jongh and Tommi Kainu

Kirsten Winther,

Chairman of the board


Kirsten Winther is investment manager at Syddansk Innovation (SDI). SDI is a micro venture fund investing in high tech start-ups in the pre-seed face. Kirsten is responsible for SDI´s investment in a portfolio of start-ups covering the field of biotech, medtech, IoT and robotics. Prior to joining SDI, Kirsten has gained experience in the fields of business development, M&A, sales management and investment in energy projects, both in large corporations and as commercial director and co-investor in a start-up within greentech. Kirsten holds a MSc(econ).

Allan Rosetzsky,

Board member


Allan Rosetzsky is MD and consultant in general medicine and surgery. He has 14 years of experience as medical director at Rhône-Poulenc (now Sanofi-Aventis), where he was responsible for clinical development and medical affairs, including medical evaluation in connection with license opportunities. He founded the CRO KLIFO in 1994, which became operational in eight countries before it was sold in 2007. In 2010 he joined startup Expres2ion Biotechnologies (now a NASDAQ First North listed company) as major investor and director of the board and was fulltime operational in the company during the set-up period. In addition, Allan is currently also director of the board at AdaptVac.

Wian de Jongh,

Board member


Wian is CEO of AdaptVac and leads its SARS-CoV-2 vaccine development efforts. He has >10 years experience as Chief Scientific Officer and Co-founder of NASDAQ First North listed ExpreS2ion Biotechnologies. At Expres2ion he was involved in screening of a large number of possible vaccine candidates and the in development and CMC transfer activities of two malaria vaccines. Wian holds a Ph.D in Biotechnology.

Tommi Kainu, M.D. & Ph.D.,

Board member


Tommi Kainu has >20 years of experience in the biomedical industry and research including executive, advisory and scientific roles. He is currently Chief Business Officer at Unikum Therapeutics. Immediately prior, he served as Executive Vice President and Chief Business Officer at Bavarian Nordic A/S where his responsibilities included business and corporate development, sales, marketing, and government affairs. Earlier in his career, Tommi was Managing Director and Partner at the Boston Consulting Group. Tommi holds MD and PhD-degrees from the University of Tampere Medical School, Finland.